MED Alliance Solutions
Magnus Medical is a privately held neurotechnology company that commercializes the FDA-cleared SAINT neuromodulation system, providing rapid 5-day fMRI-guided transcranial magnetic stimulation treatment for adults with treatment-resistant major depressive disorder, sold to hospitals and outpatient psychiatry clinics through a Verified SAINT Provider network.
- Company typePrivate
- Founded2020
- HeadquartersJoliet, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MED Alliance Solutions does
Magnus Medical, Inc. is a privately held neurotechnology company founded in 2020 and headquartered in Burlingame, California. It holds the exclusive worldwide license from Stanford University's Brain Stimulation Lab to commercialize SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), an FDA-cleared, non-invasive neuromodulation system for the treatment of major depressive disorder (MDD) in adults who have not achieved satisfactory improvement from prior antidepressant medications. SAINT combines functional MRI-guided personalized targeting with accelerated intermittent theta-burst stimulation (aiTBS), delivering 10 sessions per day over 5 consecutive days for a total dose of 90,000 pulses, and reports 79-90% remission rates in clinical trials versus weeks-to-months timelines for standard TMS or pharmacotherapy.
The core product is the SAINT Neuromodulation System, an FDA 510(k)-cleared medical device (K220177) with Breakthrough Device Designation. The system relies on a proprietary targeting algorithm that analyzes patient fMRI brain scans to identify the subregion of the left dorsolateral prefrontal cortex most strongly anticorrelated with the subgenual anterior cingulate cortex, enabling per-patient stimulation coordinates rather than one-size-fits-all conventional TMS. Magnus has secured first-ever NTAP (2023) and NTAPC (2024) reimbursement approvals from CMS for interventional psychiatry, with procedure billing under CPT codes 0889T-0892T.
Magnus monetizes through three revenue streams: (1) hardware sales of the SAINT Neuromodulation System to Verified SAINT Provider clinics and hospitals, (2) licensing of the SAINT brand and technology to certified providers, and (3) downstream treatment procedure revenue reimbursed via Medicare NTAP/NTAPC, commercial payers on prior-authorization basis, and self-pay. Go-to-market is enterprise field sales targeting hospitals, academic medical centers, and outpatient psychiatry practices, supported by a public Verified SAINT Provider directory that drives patient referrals. As of 2025, the provider network spans at least 10 US states and includes Stanford, UPMC, UTHealth Houston, UAMS, Sutter Health, MUSC, Atrium/Advocate, OhioHealth, and others. The company is venture-backed, having closed a Series B in 2025 with Khosla Ventures, Mubadala, Dolby Family Ventures, JAZZ Venture Partners, Red Tree Venture Capital, and MAJ Invest.
MED Alliance Solutions firmographics
Firmographics- Name
- MED Alliance Solutions
- Legal name
- Magnus Medical, Inc.
- Website
- https://magnusmedical.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Magnus Medical is a privately held neurotechnology company that commercializes the FDA-cleared SAINT neuromodulation system, providing rapid 5-day fMRI-guided transcranial magnetic stimulation treatment for adults with treatment-resistant major depressive disorder, sold to hospitals and outpatient psychiatry clinics through a Verified SAINT Provider network.
- Ownership category
- akta.pro rank
MED Alliance Solutions industry classification
Industry- Product category
- Neuromodulation Medical Devices
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Condition-specific Digital Therapeutics (DTx) (HLACANAA)
- akta.pro secondary industry
- Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)
Keywords
Where MED Alliance Solutions is headquartered
LocationHeadquarters
- HQ city
- Joliet
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MED Alliance Solutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- SAINT Neuromodulation System Hardware: Magnus sells the SAINT Neuromodulation System equipment to Verified SAINT Provider clinics and hospitals for use in delivering treatment to patients.
- Treatment Procedure Revenue: Healthcare providers bill for SAINT treatment using CPT codes 0889T, 0890T, 0891T, 0892T. Medicare has approved NTAP for hospital sites and NTAPC for outpatient settings, enabling reimbursement for the procedure.
- Provider Network Licensing: Magnus licenses the SAINT technology and brand to Verified SAINT Providers who meet certification requirements, generating recurring licensing revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medicare Fee-for-Service Coverage |
| Other | Multi-year contract | Commercial/Private Insurance |
| Other | Pay-as-you-go | Self-Pay / Out-of-Pocket |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
MED Alliance Solutions product offering
Product offeringCore offering
Magnus Medical develops and commercializes the SAINT Neuromodulation System, an FDA-cleared medical device that uses functional MRI (fMRI)-guided personalized targeting combined with accelerated intermittent theta-burst stimulation (aiTBS) to deliver rapid remission from treatment-resistant Major Depressive Disorder (MDD) in just five days. The system is sold and licensed to Verified SAINT Provider hospitals, academic medical centers, and outpatient psychiatry clinics, who deliver the SAINT clinical protocol to adult patients who have not responded to prior antidepressant medications.
Product overview
Magnus Medical offers a single unified product platform: the SAINT Neuromodulation System (also called SAINT Depression Therapy or Stanford Accelerated Intelligent Neuromodulation Therapy). SAINT is an FDA-cleared, noninvasive neuromodulation therapy that delivers rapid remission from treatment-resistant depression in just five days using personalized fMRI-guided brain targeting combined with accelerated intermittent theta-burst stimulation (aiTBS).
Differentiator
Problem solved
Functional benefit
Brands
- SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy): FDA-cleared neuromodulation therapy for treatment-resistant major depressive disorder (MDD) that uses fMRI-guided TMS to deliver rapid remission in 5 days.
Products and services
- SAINT Neuromodulation System The SAINT Neuromodulation System is an FDA-cleared (K220177) non-invasive medical device that uses fMRI-guided personalized targeting combined with accelerated intermittent theta-burst stimulation (aiTBS) to deliver rapid remission from treatment-resistant Major Depressive Disorder (MDD) in adults who have not responded to prior antidepressant medications. The system is sold or licensed to Verified SAINT Provider hospitals, academic medical centers, and outpatient psychiatry clinics, and delivers 10 sessions per day (1,800 pulses per session) over 5 consecutive days, totaling 90,000 pulses per treatment course.
Quantifiable outcome
- 79-90% remission rate in clinical trials for treatment-resistant depression
- +3 more outcomes
Companies that use MED Alliance Solutions
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
MED Alliance Solutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
MED Alliance Solutions partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Stanford UniversitycoreStanford University developed SAINT technology through the Brain Stimulation Lab and licensed it exclusively to Magnus Medical in 2020 for further development and commercialization. The company holds exclusive rights to issued U.S. patents assigned to Stanford University.
- Stanford University Medical CentercoreVerified SAINT Provider offering SAINT treatment to patients at 211 Quarry Road, Palo Alto, CA. One of the original clinical trial sites for SAINT development.
- UPMC (University of Pittsburgh Medical Center)coreVerified SAINT Provider at the Center for Interventional Psychiatry in Pittsburgh, PA, offering SAINT treatment as part of their behavioral health services.
- UTHealth HoustoncoreVerified SAINT Provider at the Center for Interventional Psychiatry in Houston, TX, offering SAINT treatment to patients in the Texas region.
- University of Arkansas Medical Sciences (UAMS)coreVerified SAINT Provider at UAMS Interventional Psychiatry department in Little Rock, AR, offering SAINT treatment.
- Sutter HealthcoreVerified SAINT Provider at the Sutter Center for Psychiatry in Sacramento, CA, part of the Sutter Health network.
- Los Angeles TMS InstitutecoreVerified SAINT Provider in Los Angeles, CA, founded by Dr. Ian Cook, a recognized expert in TMS and depression treatment.
- LSU Health Sciences Center / LCMC HealthcorePartner site where veterans and patients receive SAINT treatment through the VA Community Care Network. Located at University Medical Center New Orleans in partnership with LSU and Tulane.
- Department of Defensecore$11.6M DoD-supported pivotal study evaluating SAINT for postpartum depression. First patient enrolled at University of Massachusetts in multisite study.
- Salma HealthminorVerified SAINT Provider with multiple locations including Fremont, La Jolla, and Laguna Hills in California.
- OhioHealthminorVerified SAINT Provider in Columbus, OH offering SAINT treatment as part of their neuroscience and behavioral health services.
- Medical University of South Carolina (MUSC)minorVerified SAINT Provider in Charleston, SC, offering SAINT treatment through their psychiatry department.
- Atrium Health / Advocate HealthminorVerified SAINT Provider in Charlotte, NC offering SAINT treatment through their behavioral health brain stimulation program.
- Neuro Wellness TMS Centers of AmericaminorVerified SAINT Provider in Coral Springs, FL specializing in TMS and neuromodulation treatments.
Scale indicators7 records
Recent moves10 records
Expansion highlights8 records
MED Alliance Solutions competitors and assessment
Company assessmentEmerging players
- Sooma: Sooma develops transcranial direct current stimulation (tDCS) devices for depression and pain. It is an emerging neuromodulation player with a different modality but overlapping clinical indication (MDD).
- Flow Neuroscience: Flow Neuroscience offers a home-based TMS device paired with behavioral therapy for depression, primarily in Europe. It is an emerging player addressing the same treatment-resistant depression patient population with a different (decentralized) delivery model.
- Motif Neurotech: Motif Neurotech is developing minimally-invasive brain stimulation for psychiatric conditions including depression. It is an early-stage player with thematic overlap to Magnus in interventional psychiatry.
- NeoSync: NeoSync is developing synchronized transcranial magnetic stimulation (sTMS) for treatment-resistant depression. It is an emerging player in the TMS category targeting the same patient population with a different mechanism.
Broad incumbents
- Magstim: Magstim is a long-established manufacturer of TMS stimulation systems used in clinical research and depression treatment globally. It is a broad incumbent in the TMS equipment category that Magnus competes within, but lacks Magnus's accelerated, fMRI-guided protocol.
- MagVenture: MagVenture manufactures TMS systems widely used in research and clinical psychiatry, including for depression. As a broad incumbent, it overlaps with Magnus in TMS equipment but does not offer the SAINT-specific fMRI-guided, accelerated protocol.
Others
- Axsome Therapeutics: Axsome Therapeutics markets Auvelity, an FDA-approved oral therapy for major depressive disorder. It is not a neuromodulation peer but competes for the same treatment-resistant MDD patient population via a pharmaceutical mechanism.
- COMPASS Pathways: COMPASS Pathways is developing psilocybin therapy for treatment-resistant depression. It is a non-device but adjacent interventional-psychiatry peer pursuing rapid-acting depression treatment through a different modality.
Direct peers
- Brainsway: Brainsway develops Deep TMS systems with FDA-cleared indications including depression, OCD, and smoking addiction. It competes directly with Magnus in interventional psychiatry using a different coil-based approach to stimulation.
- Neuronetics: Neuronetics markets NeuroStar, the leading conventional TMS system for treatment-resistant depression. It is the most direct U.S. competitor to SAINT, targeting the same patient population with a longer (6-9 week) course of therapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
MED Alliance Solutions social profiles
Digital presenceMED Alliance Solutions compliance and trust
Trust signalCompliance1 record
MED Alliance Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
MED Alliance Solutions leadership team
Management profileNumber of profiles
Profiles9 records
MED Alliance Solutions funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MED Alliance Solutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MED Alliance Solutions
What does MED Alliance Solutions do?
Magnus Medical develops and commercializes the SAINT Neuromodulation System, an FDA-cleared medical device that uses functional MRI (fMRI)-guided personalized targeting combined with accelerated intermittent theta-burst stimulation (aiTBS) to deliver rapid remission from treatment-resistant Major Depressive Disorder (MDD) in just five days. The system is sold and licensed to Verified SAINT Provider hospitals, academic medical centers, and outpatient psychiatry clinics, who deliver the SAINT clinical protocol to adult patients who have not responded to prior antidepressant medications.
Is MED Alliance Solutions a public or private company?
MED Alliance Solutions is a private company. It is classified as venture growth investor backed and is currently operating.
When was MED Alliance Solutions founded?
MED Alliance Solutions was founded in 2020. It employs 1 to 10 people.
Where is MED Alliance Solutions based?
MED Alliance Solutions is headquartered in Joliet, United States, in the North America region.
How does MED Alliance Solutions make money?
Three revenue lines are on record. SAINT Neuromodulation System Hardware is the primary driver. The others are treatment Procedure Revenue and provider Network Licensing.
Who are MED Alliance Solutions's main competitors?
Emerging players on record are Sooma, Flow Neuroscience, Motif Neurotech and NeoSync. Broad incumbents are Magstim and MagVenture. Others are Axsome Therapeutics and COMPASS Pathways. Direct peers are Brainsway and Neuronetics.
Does MED Alliance Solutions have an API?
No public API is recorded for MED Alliance Solutions.
What industry is MED Alliance Solutions in?
MED Alliance Solutions's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination). Its SIC code is 3841.